剪切波弹性成像联合Ki-67指数作为浸润性乳腺癌新辅助化疗病理反应的新型预测方法
这项前瞻性研究纳入66例浸润性乳腺癌患者,评估剪切波弹性成像(SWE)及SWE联合Ki-67指数对新辅助化疗(NAC)病理反应的预测价值。结果显示ΔEmean(t2)与Ki-67指数诊断性能较好,两者相关性较弱(r=0.29),联合构建的predRCB模型诊断性能优于单独使用SWE参数或Ki-67指数。作者认为联合Ki-67可能提高SWE预测能力,但需多中心前瞻性大样本研究验证。
要点
- ΔEmean(t2)与Ki-67指数预测病理反应(RCB-I反应和RCB-III耐药)的诊断性能显著优于其他参数。
- ΔEmean(t2)与Ki-67指数作为诊断预测指标的相关性显著较弱(r=0.29)。
- predRCB联合模型诊断性能优于单独SWE参数或Ki-67指数。
核心结论
- 研究结果提示在SWE结果中加入Ki-67指数可能提高SWE的预测能力,并有助于乳腺癌患者治疗方案个体化。
- 作者认为这些结果应通过未来开展更大 cohort 的多中心前瞻性研究进行验证。
研究设计与样本
- 前瞻性研究,2014年7月至2015年11月招募66例符合条件的浸润性乳腺癌患者。
- 在活检前1天(t0,弹性E0)、下一NAC周期前1天(t1-t5,E1-E5)及手术前1天(t6,E6)采用定量SWE评估肿瘤硬度。
- 将第一和第二NAC周期后SWE参数的相对变化作为变量[ΔE(t1)、ΔE(t2)]。
- 病理反应按残留癌症负荷(RCB)方案分类。
- 比较SWE参数、Ki-67指数及线性回归模型确定的预测RCB(predRCB)评分的预测诊断性能。
主要发现
- 部分免疫组化和分子因素及SWE参数在三个RCB组间有显著差异。
- ΔEmean(t2)和Ki-67在预测病理反应(RCB-I反应和RCB-III耐药)方面诊断性能显著优于其他参数。
- ΔEmean(t2)与Ki-67指数作为诊断预测指标的相关性显著较弱(r=0.29)。
- predRCB联合模型(结合ΔEmean(t2)和Ki-67指数的多变量线性回归模型)诊断性能优于单独SWE参数和Ki-67指数。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出这些结果应通过未来开展更大 cohort 的多中心前瞻性研究进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated shear wave elastography (SWE) and SWE combined with the Ki-67 index as novel predictive modalities for the pathological response of invasive breast cancer to neoadjuvant chemotherapy (NAC). METHODS: The prospective study recruited 66 eligible patients from July 2014 to November 2015. Tumour stiffness, which corresponds with tumour progression and invasiveness, was assessed by quantitative SWE 1 d before biopsy (time point t0, elasticity E0), 1 d before next NAC cycle (t1-t5, E1-E5), and 1 d before surgery (t6, E6). The relative changes in SWE parameters after the first and second NAC cycles were considered as the variables [ΔE (t1), ΔE (t2)]. The pathological response was classified according to the residual cancer burden (RCB) protocol. Correlations between RCB scores and variables were evaluated. The predictive diagnostic performances of SWE parameters, Ki-67 index, and the predictive RCB (predRCB) score determined by a linear regression model were compared. RESULTS: Some immunohistochemical and molecular factors and SWE parameters were significantly different among the three RCB groups. The ΔEmean (t2) and Ki-67 had significantly better diagnostic performance than other parameters regarding predicting the pathological response (the RCB-I response and RCB-III resistance). However, the correlation between ΔEmean (t2) and Ki-67 index was significantly weaker as a diagnostic predictor (r = 0.29). We generated a new predictive modality, predRCB, which is a multivariable linear regression model that combines ΔEmean (t2) and the Ki-67 index. The predRCB modality showed better diagnostic performance than SWE parameters and Ki-67 index alone. CONCLUSION: Our findings highlight the potential utility for adding the Ki-67 index to the SWE results, which may improve the predictive power of SWE and facilitate personalising the treatment regimens of patients with breast cancer. These results should be validated in the future by performing a multicentre prospective study with a larger cohort.
引用
- Ma Y, Zhang S, Zang L, et al. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer. Eur J Cancer. 2016. PMID: 27821323. doi:10.1016/j.ejca.2016.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。